These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1729 related items for PubMed ID: 26478208

  • 1. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, Ungvari GS, Correll CU, Chiu HF, Xue Y, Tian TF, Wu AS, Ma X, Wang G.
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, Sambunaris A, Patkar AA.
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D.
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [Abstract] [Full Text] [Related]

  • 5. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES, Howard C, Khan DA, Carmody TJ.
    Psychosomatics; 2012 Apr; 53(1):75-80. PubMed ID: 22221724
    [Abstract] [Full Text] [Related]

  • 6. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, Chen LJ, Li MD, Ning YP.
    J Psychiatr Res; 2018 Nov; 106():61-68. PubMed ID: 30278319
    [Abstract] [Full Text] [Related]

  • 7. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 9. Trial of Psilocybin versus Escitalopram for Depression.
    Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ.
    N Engl J Med; 2021 Apr 15; 384(15):1402-1411. PubMed ID: 33852780
    [Abstract] [Full Text] [Related]

  • 10. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.
    Clin Drug Investig; 2007 Apr 15; 27(7):481-92. PubMed ID: 17563128
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T, Dehelean P, Nuss P, Raba V, Picarel-Blanchot F, de Bodinat C.
    J Affect Disord; 2016 Jul 15; 199():6-12. PubMed ID: 27054610
    [Abstract] [Full Text] [Related]

  • 16. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM, Llorca PM, Despiegel N, Verpillat P.
    Encephale; 2004 Jul 15; 30(2):158-66. PubMed ID: 15107719
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
    Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H.
    Depress Anxiety; 2010 Oct 15; 27(10):964-76. PubMed ID: 20734365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 87.